Entrada Therapeutics, Inc. (TRDA)

NASDAQ: TRDA · IEX Real-Time Price · USD

16.98

+0.10 (0.59%)

At close: Jul 19, 2024, 4:00 PM

16.95

-0.03 (-0.18%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Entrada Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	162.87	129.01	0	0	0	0
Revenue Growth (YoY)	544.79%	-	-	-	-	-
Gross Profit	162.87	129.01	0	0	0	0
Selling, General & Admin	33.75	32.29	30.64	15.2	5.57	3.61
Research & Development	105.39	99.88	66.61	35.93	21.1	8.22
Operating Expenses	139.14	132.18	97.25	51.13	26.67	11.82
Operating Income	23.73	-3.16	-97.25	-51.13	-26.67	-11.82
Interest Expense / Income	0	0	0	-0.03	0.14	0
Other Expense / Income	-16.78	-15.22	-2.63	0.06	-0.29	-6.72
Pretax Income	40.51	12.06	-94.62	-51.16	-26.52	-5.1
Income Tax	17.02	18.74	0	0	0	0
Net Income	23.49	-6.69	-94.62	-51.16	-26.52	-5.1
Shares Outstanding (Basic)	33	33	31	6	1	7
Shares Outstanding (Diluted)	35	33	31	6	1	7
Shares Change	7.46%	5.61%	399.27%	467.09%	-83.63%	-
EPS (Basic)	0.70	-0.20	-3.02	-8.16	-24.00	-0.76
EPS (Diluted)	0.64	-0.20	-3.02	-8.16	-24.00	-0.76
Free Cash Flow	-93.9	134.19	-96.67	-55.44	-27.89	-11.43
Free Cash Flow Per Share	-2.80	4.06	-3.09	-8.85	-25.23	-1.69
Gross Margin	100.00%	100.00%	-	-	-	-
Operating Margin	14.57%	-2.45%	-	-	-	-
Profit Margin	14.42%	-5.18%	-	-	-	-
Free Cash Flow Margin	-57.65%	104.01%	-	-	-	-
Effective Tax Rate	42.02%	155.45%	-	-	-	-
EBITDA	43.74	14.9	-92.72	-50.07	-26.05	-5
EBITDA Margin	26.86%	11.55%	-	-	-	-
Depreciation & Amortization	3.23	2.84	1.9	1.12	0.33	0.1
EBIT	40.51	12.06	-94.62	-51.19	-26.38	-5.1
EBIT Margin	24.87%	9.34%	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).